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Abstract
Background: Abnormal DNA methylation is well established for breast cancer and contributes to its progression by
silencing tumor suppressor genes. DNA methylation profiling platforms might provide an alternative approach to
expression microarrays for accurate breast tumor subtyping. We sought to determine whether the distinction of the
inflammatory breast cancer (IBC) phenotype from the non-IBC phenotype by transcriptomics could be sustained by
methylomics.
Methodology/Principal Findings: We performed methylation profiling on a cohort of IBC (N=19) and non-IBC (N=43)
samples using the Illumina Infinium Methylation Assay. These results were correlated with gene expression profiles.
Methylation values allowed separation of breast tumor samples into high and low methylation groups. This separation was
significantly related to DNMT3B mRNA levels. The high methylation group was enriched for breast tumor samples from
patients with distant metastasis and poor prognosis, as predicted by the 70-gene prognostic signature. Furthermore, this
tumor group tended to be enriched for IBC samples (54% vs. 24%) and samples with a high genomic grade index (67% vs.
38%). A set of 16 CpG loci (14 genes) correctly classified 97% of samples into the low or high methylation group.
Differentially methylated genes appeared to be mainly related to focal adhesion, cytokine-cytokine receptor interactions,
Wnt signaling pathway, chemokine signaling pathways and metabolic processes. Comparison of IBC with non-IBC led to the
identification of only four differentially methylated genes (TJP3, MOGAT2, NTSR2 and AGT). A significant correlation between
methylation values and gene expression was shown for 4,981 of 6,605 (75%) genes.
Conclusions/Significance: A subset of clinical samples of breast cancer was characterized by high methylation levels, which
coincided with increased DNMT3B expression. Furthermore, an association was observed with molecular signatures
indicative of poor patient prognosis. The results of the current study also suggest that aberrant DNA methylation is not the
main force driving the molecular biology of IBC.
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Introduction
Epigenetic changes, in particular DNA methylation, are
recognized as one of the most common forms of molecular
alteration in human cancer [1,2]. Two changes in DNA
methylation patterns are observed in cancer: i) a global
hypomethylation, which has been associated with increased
chromosomal instability, the reactivation of transposable elements
and loss of imprinting; and ii) hypermethylation of CpG islands
located in the promoter regions of tumor suppressor genes, which
has conventionally been associated with transcriptional silencing in
cancer [3,4]. The DNA methylation patterns associated with the
development and progression of cancer have potential clinical use
[5]. First of all, the changes in DNA methylation patterns are
characteristic of cancer cells, specific to the cancer type and occur
at the early stages of cancer development, making them candidate
biomarkers for early and specific cancer detection [6]. Second,
DNA methylation patterns are of potential value for prognosis, as
they might also reflect both the growth advantage and malignant
potential of cancer cells. Third, changes in DNA methylation can
affect genes influencing response to therapy, which makes these
potential markers of clinical response.
Breast cancer is a heterogeneous disease that comes in several
distinct clinical and histological phenotypes. Clinical progression is
difficult to predict using the current prognostic factors and
treatment is therefore not as effective as it should be. Genome-
wide gene expression profiling by complementary DNA micro-
array has been used for accurate tumor subtyping based on a
defined molecular signature [7,8]. DNA methylation profiling
might provide an alternative or complementary tactic to classify
breast cancer and, in this way, provide clinicians with a better
understanding of individual tumor biology and an opportunity to
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associated DNA methylation patterns with histological patterns of
tumor growth [9,10], histological tumor grade [11–13] and with
hormone receptor and Her2/neu expression [12,14–16]. Using an
array-based platform with more than 800 cancer-related genes,
Holm et al. have recently revealed that the molecular breast
cancer subtypes, especially basal-like, luminal A and luminal B
tumors, harbor specific methylation profiles [17].
In the present study, we undertook methylation profiling using
the Infinium Human Methylation27 BeadChips (Illumina, San
Diego, CA, USA) in a series of breast cancer cases to determine
whether subsets of breast cancer can be distinguished by their
profiles of methylation. In particular, we investigated the
possibility that the inflammatory breast cancer (IBC) phenotype
is characterized by a specific DNA methylation pattern. IBC is a
particularly aggressive manifestation of primary epithelial breast
tumors and affects ,5% of women with breast cancer [18,19].
Patients with IBC are often misdiagnosed due to the lack of
knowledge about symptoms. Furthermore, no specific therapies
have been developed for the treatment of IBC. Prognosis therefore
remains dismal, with 5-year survival rates ranging from 30% to
50%. The absence of tailored treatment for IBC is due in part to a
lack of understanding of the biological factors that influence the
IBC disease course and outcome. Elucidating the molecular
characteristics of IBC will help the development of novel
diagnostic tools and innovative, targeted therapies for patients
with IBC. Investigation of methylation in IBC has so far been
restricted to studies focused on individual tumor suppressor genes,
using quantitative methylation-specific PCR [20,21]. These studies
have reported differential methylation of certain genes between
IBC and non-IBC, leading us to consider the possibility of a
unique methylation profile for IBC.
Methods
Patients’ samples
Breast tumor and normal breast tissue samples were retrieved
from the tissue bank of the General Hospital Sint-Augustinus
(Antwerp, Belgium). Clinical and pathological data are stored in a
database in accordance with hospital privacy rules. Specimens
were brought to the pathologists immediately after resection and
part of the tissue was placed in liquid nitrogen and subsequently
stored at 2180uC. A total of 19 patients with IBC and 43 patients
with non-IBC were included in this study. In addition, we
collected 10 normal breast tissues from healthy controls (mean age
36y, range 25–47y). IBC was diagnosed according to the criteria
mentioned in the AJCC (American Joint Committee on Cancer)-
TNM staging system [22]. All patients with IBC showed diffuse
enlargement of the involved breast of sudden onset. There was
erythema and edema of the skin involving more than one third of
the breast. The presence of dermal lymphatic invasion as an
isolated observation was not sufficient for the diagnosis of IBC and
was not necessary for the diagnosis either. Tumor characteristics
are provided in Table 1.
Ethical approval for collection of clinical material was obtained
from the Sint-Augustinus Ethics Committee.
Genomic DNA isolation and quality assessment
DNA extractions from fresh frozen tissues were performed using
the QIAamp DNA Mini Kit (Qiagen, Valencia, Ca) according to
the manufacturer’s instructions. Genomic DNA quality was
assessed by low agarose gel (0.5%) electrophoresis under low
power voltage. Thresholds for genomic DNA quality check were:
a) showing a high molecular band (,40 Kb) in 0.6% agarose gel
low-voltage electrophoresis (3 hrs) and no strong band of low
molecular weight (,2.0 Kb); b) OD260/280 and OD260/230
within a range of 1.0–3.0.
Bisulphite conversion
Bisulphite conversion of genomic DNA was done with the EZ
DNA methylation Kit (Zymo Research, D5002) by following the
manufacturer’s protocol with modifications for the Illumina
Infinium Methylation Assay. Briefly, one microgram of genomic
DNA was first mixed with 5 ml of M-Dilution Buffer and
incubated at 37uC for 15 minutes and then mixed with 100 ml
of CT Conversion Reagent prepared as instructed in the protocol.
Mixtures were incubated in a thermocycler for 16 cycles at 95uC
for 30 seconds and 50uC for 60 minutes. Bisulphite-converted
DNA samples were loaded onto 96-column plates provided in the
kit for desulphonation and purification as instructed in the
protocol. Concentration of eluted DNA was measured using a
Nanodrop-1000. Bisulphite-converted samples were used for chip
analysis as described below without any delay.
Illumina Infinium Human Methylation27 BeadChip
Bisulphite-converted genomic DNA was analyzed using Illumi-
na’s Infinium Human Methylation27 Beadchip Kit (WG-311-1202)
(performed at the DNA Microarray Core, Johns Hopkins
University). Data can be freely downloaded from the web
page http://www.tcrg.be/en/page6/page13/epigenetics.html. The
beadchip contains 27,578 CpG loci covering more than 14,000
human RefSeq genes at single-nucleotide resolution. Chip process
and data analysis were performed by using reagents provided in the
kit and by following the manufacturer’s manual. Briefly, 4 mlo f
bisulphite-converted genomic DNA was denatured in 0.014N
Table 1. Tumor characteristics.
Clinicopathological
features IBC (N=19)
Non-IBC
(N=43) P-value
Patients’ ages (y) 0.978
Mean 59,6 59,7
Range 45–79 30–89
Tumor stage ,0.001
I 0 (0%) 12 (28%)
II 0 (0%) 16 (37%)
III 12 (63%) 12 (28%)
IV 7 (37%) 3 (7%)
Histological tumor grade 0.049
Well 0 (0%) 9 (21%)
Moderate 7 (37%) 18 (42%)
Poor 12 (63%) 16 (37%)
Estrogen receptor 0.608
Positive 12 (63%) 30 (70%)
Negative 7 (37%) 13 (30%)
Progesterone receptor 0.479
Positive 7 (37%) 20 (46%)
Negative 12 (63%) 23 (54%)
HER2 amplification 0.270
Positive 8 (42%) 12 (28%)
Negative 11 (58%) 31 (72%)
doi:10.1371/journal.pone.0012616.t001
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reagents and buffer for 20–24 hours at 37uC. Samples were
fragmented. 12 ml of each sample was loaded onto a 12-sample
chip and the chips were assembled into a hybridization chamber as
instructed in the manual. After incubation at 48uC for 16–20 hours,
chips were washed with wash buffers provided in the kit and
assembled and placed into a fluid flow-through station for primer-
extension reactionand stainingwith reagentsand buffersprovided in
the kit. Polymer-coated chips were image-processed in Illumina’s
iScan scanner. Data were extracted using BeadStudio v3.0 software.
Methylation values for each CpG locus are expressed as a beta (b)-
value, representing a continuous measurement from 0 (completely
unmethylated) to 1 (completely methylated). This value is based on
following definition and calculation:
b-value = (signal intensity of methylation-detection probe)/
(signal intensity of methylation- detection probe + signal intensity
of non-methylation-detection probe).
As a positive control for methylation analysis, we used Human
HCT116 methylated DNA (Cat# D5014-2, Zymo Research). As
a negative control for methylation analysis, Human HCT116
DKO DNA (DNA methyltransferase double knock-out cells
(DNMT1 and DNMT3b), prepared by Core Facility) was used.
Replicate samples (N=3) were included to assess inter-array
reproducibility.
Data analysis
Data were analyzed using Bioconductor in R (http://www.
bioconductor.org). Sixty-eight CpG loci for which the detection p-
value was .0.05 in 25% of samples were excluded from analysis as
were 28 CpG loci showing a b-value of ,0.5 in the Human
HCT116 methylated DNA sample and 4,067 CpG loci showing a
mean b-value of .0.2 in the Human HCT116 DKO DNA
samples. Analysis was subsequently restricted to the remaining
23,496 CpG loci (12,956 genes), 18,742 located within CpG
islands and 4,754 located outside of these regions.
Unsupervised hierarchical clustering analysis with the Euclidean
distance and complete linkage algorithm was used to create a
heatmap with associated dendrogram. A Prediction Analysis of
Microarrays (PAM) and a two-sided t-test were used to identify
differentially methylated CpG loci. Selection of the most
significantly differentially methylated CpG loci between samples
was based on (1) a b-value difference of .0.17 [23] and (2) a P-
value of ,0.0001. Functional characteristics of genes of interest
were examined with a gene set enrichment analysis using
hypergeometric testing for KEGG pathways.
Gene expression profiling
Gene expression profiling of these breast tumors (N=57) was
performed as previously described [24]. Briefly, extracted RNA
was hybridized onto the Affymetrix HGU133 plus 2.0 array in
collaboration with the VIB Micrarray Facility (UZ-Gasthuisberg,
Leuven, Belgium). Perfect match fluorescence intensities were
background-corrected, mismatch-adjusted, normalized and sum-
marized to yield log2-transformed gene expression data using the
GCRMA algorithm. A pairwise Pearson correlation analysis was
used to assess the association between methylation levels and gene
expression levels.
Results
Unsupervised hierarchical clustering of normal breast
tissues and breast tumors
DNA methylation levels were measured using the Illumina
Infinium HumanMethylation27 BeadChips in breast tumor
samples from 19 patients with IBC and 43 patients with non-
IBC and in normal breast tissue samples from 10 healthy women.
Unsupervised hierarchical cluster analysis of the 1,000 most
varying b-values (largest s.d.) of the breast tumor (N=62) and
normal breast tissue samples (N=10) separated samples into three
distinct groups (average silhouette width 0.165, P,0.00001): one
group consisting of 11 tumor samples (blue color bar in Figure 1),
one group consisting of 39 tumor samples (red color bar in
Figure 1) and one group that included all 10 normal samples and
12 tumor samples (green color bar in Figure 1). The normal breast
tissue samples showed little variation in methylation profiles, with
a mean s.d. of b-value of 0.02. The three sample clusters
significantly differed in mean b-values (P,0.00001). The low b
group (green color bar in Figure 1) had a mean b-value of 0.25, the
intermediate b group (red color bar in Figure 1) had a mean b-
value of 0.38 and the high b group (blue color bar in Figure 1) had
a mean b-value of 0.52. Of the 1,000 most varying CpG loci, 835
were located within a CpG island (dark grey color bar in Figure 1)
and 165 were located outside of a CpG island (grey color bar in
Figure 1). Within the low and intermediate b groups, mean b-
values for CpG loci outside a CpG island were significantly higher
than mean b-values for CpG loci within a CpG island
(P,0.00001) (Figure 2). In contrast, within the high b group,
mean b-values for CpG loci outside a CpG island were
significantly decreased (P,0.00001).
Supervised analysis of methylation in breast tumors vs.
normal breast tissues
To identify the CpGs showing the most significant tumor-
specific changes in methylation relative to normal controls, a mean
b-value was determined for all 62 breast tumor samples and
compared with the corresponding mean b-value in the normal
breast tissue group. Using the criteria of P,0.00001 and Db
.0.17, 1,353 CpG loci (corresponding to 1,134 genes) were
identified (Table S1). For 1,037 of these CpG loci (77%) a
significant increase in methylation was observed in the group of
breast tumors. Thus, 316 CpG loci showed significant loss of
methylation in breast tumors relative to normal breast tissues.
CpG loci outside of CpG islands were significantly over-
represented in the group showing loss of methylation in breast
tumors (76% versus 18%; P,0.0001, Fisher’s exact test). To
determine the biological relevance of the differentially methylated
genes, we performed a gene set enrichment analysis using
hypergeometric testing for KEGG pathways. Genes differentially
methylated between normal breast tissues and breast tumors were
related to focal adhesion (P,0.0001), extracellular matrix receptor
interaction (P=0.0025), pathways in cancer (P=0.0049), cyto-
kine-cytokine receptor interaction (P=0.0066) and ether lipid
metabolism (P=0.0099) (Table 2).
Unsupervised hierarchical clustering of breast tumors
Unsupervised hierarchical cluster analysis of 500 most varying
b-values (largest s.d.) separated breast tumor samples into two
distinct groups (average silhouette width 0.235, P,0.0001)
(Figure 3). We refer to these clusters as low b (N=49) and high
b (N=13) tumor groups. These groups showed a mean b-value of
0.314 and 0.513, respectively (P,0.0001). The high b tumor
group was significantly enriched for breast tumor samples from
patients with distant metastasis and poor prognosis (as determined
by the 70-gene prognostic signature [25]) when compared to the
low b tumor group (P x2=0.026 and P x2=0.049, respectively).
Furthermore, the high b tumor group tended to be enriched for
IBC samples (54% and 24% of samples in the high and low b
tumor groups, respectively, were from IBC patients, P x2=0.087)
DNA Methylation Profiling
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12616Figure 2. Box plots of methylation values (b) in the low, intermediate and high b groups according to the location of a CpG locus
within a CpG island (light grey) or outside a CpG island (dark grey). Within the low and intermediate b groups, mean b-values for CpG loci
outside a CpG island were significantly higher than mean b-values for CpG loci within a CpG island. Within the high b group, mean b-values for CpG
loci outside a CpG island were significantly decreased.
doi:10.1371/journal.pone.0012616.g002
Figure 1. Hierarchical clustering of methylation values (b) from 1,000 CpG loci from 62 breast tumor and 10 normal breast tissue
samples. Columns represent samples; rows represent CpG loci. Color represents methylation level b from 0 to 1 as per color bar (red = low
methylation level; blue = high methylation level). Vertical color bar indicates location of CpG locus within the CpG island (dark grey) or outside of
CpG island (grey). Top horizontal color bar indicates sample cluster. Samples separated into three distinct groups: a group consisting of 11 tumor
samples (blue), a group consisting of 39 tumor samples (red) and a group including all normal breast tissue samples (light green) and 12 tumor
samples (dark green).
doi:10.1371/journal.pone.0012616.g001
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KEGG pathway KEGG id Genes P-value
Focal adhesion 04510 CD1D, CD8A, CD9, IL11RA, THPO, ITGA4, EPO, CD33, TPO, CD34, IL1A, FCGR1A, KIT,
CSF2, CD37
,0.0001
ECM receptor interaction 04512 FLT4, PDGFRB, LAMA1, CCND1, LAMA2, COL11A2, RELN, ACTN2, PARVG, COL1A2,
BCL2, LAMA4, COL5A2, ITGA4, CCND2, PAK7, COL1A2, PGF, PPP1CC, COL6A3, FLT1,
COL6A2, ITGA8, MYLK, EGFR, THBS4, CCND2, COL5A3, COL11A1, PRKCG
0.0025
Pathways in cancer 05200 LAMA1, LAMA2, COL11A2, RELN, COL1A2, SV2A, LAMA4, COL5A2, ITGA4, COL6A3,
COL6A2, ITGA8, THBS4, COL5A3, COL11A1
0.0049
Cytokine-cytokine receptor interaction 04060 FLT4, LEP, TNFRSF10D, CX3CL1, IL11RA, PF4V1, TNFRSF10D, TNFRSF1B, ACVR1,
TNFRSF18, CD40, CCL1, CXCL6, CCL18, TNFRSF8, EPO, TNFSF11, TPO, CCL7, FLT1,
EGFR, CCL13, IL23A, INHBC, IL1A, TNFSF8, KIT, CSF2, TGFBR1, XCL1
0.0066
Ether lipid metabolism 00565 AKR1B1 0.0099
doi:10.1371/journal.pone.0012616.t002
Figure 3. Hierarchical clustering of methylation values (b) from 500 CpG loci from 62 breast tumor samples. Columns represent
samples; rows represent CpG loci. Color represents methylation level b from 0 to 1 as per color bar (red = low methylation level; blue = high
methylation level). Samples separated into two distinct groups: a high b group consisting of 13 breast tumor samples (red dendrogram) and a low b
group consisting of 49 breast tumor samples (blue dendrogram). Bottom horizontal bar indicates the distribution of samples according to the
genomic grade index of Sotirou et al. [26] (black fill = grade 3, no fill = grade 1, grey fill = unknown), the 70-gene prognostic signature of van ’t Veer
et al. [25] (black fill = poor prognosis, no fill = good prognosis, grey fill = unknown), M status (black fill = positive, no fill = negative) and tumor
subtype (black fill = IBC, no fill = non-IBC).
doi:10.1371/journal.pone.0012616.g003
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of samples in the high and low b tumor groups, respectively, had a
high genomic grade index, P x2=0.100). There was no difference
between the two tumor groups with regard to age, tumor stage,
histological grade or ER, PR and HER2 expression.
To investigate whether the difference in methylation profiles
between breast tumors is related to differences in the DNA
methyltransferase (DNMT) machinery, we compared the expres-
sion levels of DNMT1, DNMT3a and DNMT3b mRNAs
between the high b and low b groups of breast tumors (Figure
S1). We observed increased mRNA expression levels of DNMT3b
in the high b group of breast tumors (P=0.034), with a mean
expression level of 5.76 in the low b tumor group and 6.52 in the
high b tumor group. Also for DNMT1, higher mRNA expression
levels were observed in the high b tumor group, but this difference
did not reach statistical significance (P=0.088). No difference in
DNMT3a expression between the two groups of breast tumors was
measured (P=0.620). The difference in DNMT3b expression
between the high b and low b groups of breast tumors became far
more modest when the mRNA expression levels were normalized
according to those of the cell proliferation marker PCNA
(P=0.060).
We used Prediction Analysis of Microarrays (PAM) to classify
low b and high b breast tumors by their methylation profile. PAM
builds a classifier based on a ranking of CpG loci using a penalized
t-statistic and then determines the misclassification error rate
through 10-fold cross-validation. The optimal classifier included
16 CpG loci (corresponding to 14 genes) (Figures S2 and S3).
Genes in the classifier were NIP, CHGA, OSR1, GFRA3, KLK10,
SSTR1, EFCPB2, PPARG, PRKAR1B, ABCG2, FGF5, PLTP,
GRASP and PAX7. Adding more genes to the classifier increased
the error rate, whereas fewer genes did not have enough power to
discriminate between classes. This CpG loci set showed excellent
performance, classifying 47 of 49 low b and 13 of 13 high b tumor
samples correctly for an overall success rate of 97%.
Biological relevance of differentially methylated genes in
high vs. low b breast tumors
Next, to identify differentially methylated genes between the
high b group of breast tumors (N=13) and the low b group of
breast tumors (N=49), we compared the mean b-values in both
groups for each CpG locus. We then determined their biological
relevance by performing a gene set enrichment analysis using
hypergeometric testing for KEGG pathways. Using the criteria of
P,0.0001 and Db .0.17, this analysis resulted in the identifica-
tion of 450 CpG loci (corresponding to 366 genes) (Table S2).
Genes differentially methylated between the low b and the high b
group of breast tumors appeared to be mainly related to focal
adhesion (P=0.006), galactose metabolism (P=0.0106), cytokine-
cytokine receptor interaction (P=0.0126), Wnt signaling pathway
(P=0.0221), fructose and mannose metabolism (P=0.0289),
chemokine signaling pathway (P=0.0332) and pyruvate metabo-
lism (P=0.0407) (Table 3).
Supervised analysis of methylation in IBC versus non-IBC
To identify genes differentially methylated between IBC and
non-IBC, we compared the mean b- value in IBC with the mean
b-value in non-IBC for each CpG locus. Using the criteria of
P,0.0001 and Db.0.17, only four CpG loci (corresponding to
four genes) were identified. For all CpG loci, methylation values
were increased in IBC in comparison to non-IBC. These included
TJP3 (tight junction protein-3), MOGAT2 (monoacylglycerol O-
acyltransferase 2), NTSR2 (neurotensin receptor 2) and AGT
(angiotensinogen).
Reproducibility and correlation of array results with
qMSP results
There was an excellent inter-array correlation between replicate
DNA samples obtained from two breast tumors and a Human
HCT116 DKO DNA sample (mean r
2=0.974; range 0.948–
0.992).
We compared quantitative methylation values studied by the
Infinium methylation array with previously established methyla-
tion values by qMSP in 60 breast tumor samples [20]. This was
done for five genes (APC, RASSF1A, TWIST, RARb2 and DAPK),
which corresponded to 33 CpG loci on the Infinium methylation
array. For 25 CpG loci, we observed significant positive
correlations between methylation values by the Infinium methyl-
ation array and by qMSP (Figure 4).
Correlation with gene expression
We were able to correlate methylation results with gene
expression profiles for 6,605 unique genes in 57 breast tumor
samples. We performed a Pearson correlation analysis to evaluate
correlations between methylation levels from 12,400 CpG loci and
gene expression data from 10,494 probe sets (corresponding to
these 6,605 genes). This analysis resulted in 19,884 correlation
coefficients (range: (20.83)2(+0.65)) (Figure 5). A significant
(P,0.004, FDR,0.01) inverse correlation was observed for 6,229
of the correlated pairs and a significant positive correlation was
observed for 1,534 of the correlated pairs. Overall, a significant
correlation (either positive or negative) between methylation
results and gene expression level was observed for 4,981 of
6,605 genes (75%).
Table 3. Biological function of genes differentially methylated between the low b and the high b group of breast tumors.
KEGG pathway KEGG id Genes P-value
Focal adhesion 04150 COL6A2, CCND2, COL1A2, COMP, MYL9, SHC3, FLT1, COL11A2 0.0060
Galactose metabolism 00052 AKR1B1, PFKP 0.0106
Cytokine-cytokine receptor interaction 04060 TNFRSF10D, KIT, CXCL5, CNTFR, CXCL12, CXCL2, CXCL6, CXCL3, CX3CL1, FLT1 0.0126
Wnt signaling pathway 04310 CCND2, SFRP5, SFRP1, TCF7, SFRP2, FZD2 0.0221
Fructose and mannose metabolism 00051 AKR1B1, PFKP 0.0289
Chemokine signaling pathway 04062 CXCL5, ADCY4, LYN, CXCL12, CXCL2, GNG4, CXCL6, SHC3, CXCL3, CX3CL1 0.0332
Pyruvate metabolism 00620 LDHB, AKR1B1, ACOT12 0.0407
doi:10.1371/journal.pone.0012616.t003
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High throughput methylation profiling platforms such as the
Illumina Infinium methylation assay enable extensive methylation
profiling of human tumors for a large number of genes. In the
present study, we used this approach to assess the methylation
profiles in a set of breast tumors and normal breast tissues.
Unsupervised hierarchical cluster analysis of methylation values
for the 1,000 most varying CpG loci (based on s.d.) identified three
distinct groups for which mean methylation values significantly
differed. Sample segregation was based primarily on the gain of
methylation within CpG islands and the loss of methylation
outside CpG islands relative to normal breast tissues. This is
supportive of the basic theory that CpGs located within CpG
islands in normal cells are unmethylated, whereas CpGs located
outside CpG islands are methylated with the inverse pattern
occurring in tumor cells [4]. A number of genes with higher
methylation levels in tumor samples than in normal tissue samples
proved to be involved in cancer pathways. We did not observe a
perfect separation of normal breast tissue samples from breast
tumors as a number of breast tumor samples clustered together
with the normal breast tissue samples. Since we used whole tumor
samples, this finding might be due to a confounding effect of non-
neoplastic tissue on the methylation level measured in these
samples.
The term ‘CpG island methylator phenotype’ or ‘CIMP’ was
first used to describe a distinct subset of colorectal tumors that
display high rates of concordant methylation of specific genes [27].
Subsequently, a similar phenotype has been described for a wide
range of neoplasms including tumors of the ovary [28], bladder
[29], prostate [29], stomach [30], liver [31], pancreas [32],
esophagus [33] and kidney [34], as well as melanoma [35],
neuroblastomas [36], leukemias [37] and lymphomas [38]. In
some tumor types, such as hepatocellular carcinoma, melanoma,
neuroblastoma or leukemia, CIMP has been shown to be
associated with disease progression or poor patient survival
[35,36,39,40]. In colorectal cancer, the role of CIMP in prognosis
depends on the microsatellite instability screening status [41]. In
particular, the CIMP-high and microsatellite stable tumors show a
poor prognosis. Evidence for a CIMP phenotype among breast
Figure 4. Analysis of correlation between methylation values from qMSP and the Infinium methylation array for five genes in 60
breast tumor samples. These five genes were represented by 33 CpG loci on the Infinium methylation array (y-axis). Pearson correlation values
between methylation values from qMSP and the Infinium methylation array are shown on the x-axis, with negative values representing inverse
correlations and positive values representing positive correlations. Significant correlation (P,0.01) are indicated in blue.
doi:10.1371/journal.pone.0012616.g004
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analyzing a set of breast cancer cell lines [42]. The authors
observed concurrent methylation-dependent silencing of a number
of genes in breast cancer cell lines expressing a hypermethylator
phenotype. Moreover, the hypermethylation defect in these breast
cancer cell lines was related to aberrant overexpression of
DNMT3b. These observations are in agreement with our data
in clinical samples of breast cancer. In this study, unsupervised
hierarchical cluster analysis of the methylation values of 500 CpG
loci revealed two groups of breast tumors that possess different
methylation signatures: high methylation and low methylation
breast tumors. A set of 16 CpG loci (14 genes) correctly classified
97% of samples into the low or high methylation group of breast
tumors. The high methylation group of breast tumors was more
frequently associated with poor prognosis, as determined by the
70-gene prognostic signature of van ’t Veer et al. [25]. Moreover,
these breast tumors showed increased DNMT3b mRNA levels.
These observations combine to suggest that a subset of breast
tumors could display a CIMP, although this needs to be validated
in an independent data set. Supervised analysis of the low and high
methylation group of breast tumors revealed several differentially
methylated genes implicated in different biological processes such
as focal adhesion, cytokine-cytokine receptor signaling, chemokine
signaling pathway, Wnt signaling pathway and metabolic
processes. Interestingly, some of these genes have been previously
associated with CIMP in other tumor types, such as p73, GSTP1,
SOCS-1, CACNA1G, CRABP1, NEUROG1 and RUNX3 [39,43,44].
Moreover, for other highly methylated genes, loss due to
epigenetic silencing has been previously implicated in aggressive
tumor biology. For example, methylation of the Wnt antagonists
SFRP5 and SFRP1 in breast cancer is an independent risk factor
for adverse patients survival [45,46]. The CXCL12 chemokine
binds to the CXCR4 receptor and contributes to survival,
proliferation, and migration of malignant cells. Breast cancer cells
lacking expression of CXCL12 but exhibiting CXCR4 can
metastasize to target organs that secrete CXCL12 [47]. Epigenetic
silencing of CXCL12 has been shown to increase the metastatic
potential of mammary carcinoma cells [48]. CpG hypermethyla-
tion of COL1A2 has been shown to contribute to proliferation and
migration activity of human bladder cancer [49]. The promoter
methylation status of CCND2 is associated with poor prognosis in
human epithelial ovarian cancer [50].
We were interested to compare the methylation profiles of IBC
and non-IBC, as little information is available on this topic. At the
global level, we did not find evidence for a discriminating
methylation profile. IBC samples did seem to be overrepresented
in the group of tumors showing high methylation values, but this
observation did not reach statistical significance and thus needs to
be further investigated on a larger sample population. For only
four genes (TJP3, MOGAT2, NTSR2 and AGT), methylation values
were significantly higher in IBC than in non-IBC. TJP3 functions
in maintaining tight junction integrity and in transducing
regulatory signaling events in patients with primary breast cancer
[51]. Loss of tight junction plaque molecules in breast cancer is
associated with a poor prognosis. MOGAT2 is involved in dietary
fat absorption from the small intestine. NTSR2 belongs to the G
protein-coupled receptor family and binds the ligand neurotensin.
Several reports implicate neurotensin in numerous detrimental
functions linked to neoplastic progression of several cancer types,
including pancreatic, prostate, colon and lung cancers [52]. AGT
is involved in the suppression of tumor growth and metastasis
[53,54]. The overexpression of human AGT decreases angiogen-
esis and prevents tumor sinusoids from remodeling and arterial-
ization, thus delaying tumor progression in vivo [54]. Interestingly,
several studies have indicated that, compared with non-IBC
samples, IBC samples show increased angiogenesis. Histologically,
increased vascular density and high fractions of proliferating
endothelial cells have been observed in clinical IBC samples
[19,55]. Using qRT-PCR, we demonstrated that mRNA levels of
several angiogenic growth factors and their receptors were higher
in clinical IBC samples when compared to non-IBC samples [56].
In two previous studies that focused on methylation of individual
tumor suppressor genes in IBC, we observed increased methyla-
tion frequencies for two genes, APC and RARb2, by using
quantitative methylation-specific PCR [20,21]. Also in this study,
higher methylation levels for these genes were measured in IBC
samples, but this difference did not meet our selection criteria for
differential methylation.
We observed a high level of correlation between methylation
and expression levels. Using the GoldenGate Methylation Cancer
Panel I from Illumina, O’Riain et al. observed a significant
correlation between methylation values and reduced gene
expression in follicular lymphoma for up to 28% of CpG loci
[57]. Holm et al. recently studied correlations between methyla-
tion status and gene expression in breast cancer by using a similar
technique [17]. They reported that a highly significant fraction
(72%) of the expression-methylation pairs showed inverse
correlation between relative methylation levels and expression
levels. Thus, these results are very similar to ours.
In summary, this study suggests the existence of a CIMP in a
subset of clinical samples of breast cancer. Breast tumors
displaying a CIMP also showed increased expression of DNMT3b.
Further studies are necessary to elucidate the mechanisms
underlying this phenotype and to demonstrate the potential
clinicopathological implications of a CIMP in breast cancer.
Patients with breast cancer displaying a CIMP might benefit
significantly from a targeted demethylation treatment as an
adjunct to standard chemotherapeutic regimens. The results of
the current study also suggest that aberrant DNA methylation is
not the main force driving the molecular biology of IBC. More
research needs to be done to fully understand the biological factors
that influence the IBC disease course and outcome.
Figure 5. Analysis of correlation between methylation level
and gene expression in 57 breast tumor samples. Pearson
correlation values between methylation level and mRNA expression
level are shown on the x-axis, with negative values representing inverse
correlations and positive values representing positive correlations.
Significant correlations (P,0.004, FDR,0.01) are indicated in blue.
doi:10.1371/journal.pone.0012616.g005
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Figure S1 Box plots of mRNA expression levels for DNMT3B
and DNMT1 in the high b and low b groups of breast tumors. In
the high b group of breast tumors, higher mRNA expression levels
for DNMT3B and DNMT1 were observed in comparison to the
low b group of breast tumors.
Found at: doi:10.1371/journal.pone.0012616.s001 (0.09 MB TIF)
Figure S2 Results of PAM analysis. The 62 breast tumor
samples (x-axis) are plotted against the probabilities to belong to
either class high b (green) or low b (red). For each sample, two
small circles are plotted: the red one showing the probability that
this sample belongs to the low b group of breast tumors and the
green one that it belongs to the high b group of breast tumors. The
classifier correctly predicted 47 of 49 low b and 13 of 13 high b
samples for an overall success rate of 97%.
Found at: doi:10.1371/journal.pone.0012616.s002 (0.12 MB TIF)
Figure S3 Box plots of methylation levels in the low b and high
b groups of breast tumors for the 16 CpG loci belonging to the
classifier identified by PAM analysis.
Found at: doi:10.1371/journal.pone.0012616.s003 (0.14 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0012616.s004 (0.24 MB
XLS)
Table S2
Found at: doi:10.1371/journal.pone.0012616.s005 (0.09 MB
XLS)
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